Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort

Clinical Biochemistry

Volumn 39, Issue 6, 2006, Pages 606-612

  Moridani, Majid ^a,b   Fu, Lei ^b,d   Selby, Rita ^b,d   Yun, Francisco ^d   Sukovic, Tatjana ^d   Wong, Betty ^d   Cole, David E C ^b,c,d  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Anticoagulant clinic; Anticoagulation; CYP2C9; Cytochrome P450; Drug metabolism; Polymorphism; Thrombosis clinic; Warfarin

Indexed keywords

DNA; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DNA SEQUENCE; DOSE RESPONSE; DRUG METABOLISM; ETHNOLOGY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS;

AGED; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; COHORT STUDIES; DNA PRIMERS; FEMALE; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; THROMBOSIS; WARFARIN;

EID: 33745206061     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2006.01.023     Document Type: Article

References (26)

1. Sanderson S., Emery J., and Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet. Med. 7 (2005) 97-104
2. Joffe H.V., Xu R., Johnson F.B., Longtine J., Kucher N., and Goldhaber S.Z. Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb. Haemost. 91 (2004) 1123-1128
3. Voora D., Eby C., Linder M.W., Milligan P.E., et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb. Haemost. 93 (2005) 700-705
4. Herman D., Locatelli I., Grabnar I., et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J. 5 (2005) 193-202
5. Kirchheiner J., and Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77 (2005) 1-16
6. Lee C.R., Goldstein J.A., and Pieper J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12 (2002) 251-263
7. Ingelman-Sundberg M, Daly AK, Nebert DW. Human cytochrome P450 (CYP) allele nomenclature committee home page. 2005, http://www.imm.ki.se/CYPalleles. Accessed September 27, 2005.
8. GeneSNPs Public Internet Resource, CYP2C9. 2005 http://www.genome.utah.edu/genesnps. Accessed September 27, 2005.
9. Xie H.G., Prasad H.C., Kim R.B., and Stein C.M. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 54 (2002) 1257-1270
10. Palareti G., Legnani C., Guazzaloca G., et al. Ad hoc study group of the Italian Federation of anticoagulation clinics. Risks factors for highly unstable response to oral anticoagulation: a case-control study. Br. J. Haematol. 129 (2005) 72-78
11. Yasar U., Aklillu E., Canaparo R., et al. Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations. Eur. J. Clin. Pharmacol. 58 (2002) 555-558
12. Allabi A.C., Gala J.L., Horsmans Y., et al. Functional impact of CYP2C9*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans. Clin. Pharmacol. Ther. 76 (2004) 113-118
13. Scordo M.G., Aklillu E., Yasar U., Dahl M.L., Spina E., and Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br. J. Clin. Pharmacol. 52 (2001) 447-450
14. Rubin L.A., Hawker G.A., Peltekova V., Fielding L., Ridout R., and Cole D.E.C. Determination of peak bone mass: clinical and genetic analyses in a young female Canadian cohort. J. Bone Miner. Res. 14 (1999) 633-643
15. Moridani M.Y., Wong B.Y.L., Wang W., Wei C., and Cole D.E.C. A multiplexed PCR method for genotyping polymorphic alleles of CYP2C9, the warfarin sensitive gene. Clin. Biochem. 36 (2003) 491
16. Weir B.S. Genetic Data Analysis II (1996), Sinauer Associates Inc., Sunderland, MA 91-138
17. Higashi M.K., Veenstra D.L., Kondo L.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287 (2002) 1690-1698
18. Aithal G.P., Day C.P., Kesteven P.J., and Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353 (1999) 717-719
19. Takahashi H., Wilkinson G.R., Caraco Y., et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin. Pharmacol. Ther. 73 (2003) 253-263
20. Takahashi H., and Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J. 3 (2003) 202-214
21. Tabrizi A.R., Zehnbauer B.A., Borecki I.B., McGrath S.D., Buchman T.G., and Freeman B.D. The frequency and effects of cytochrome P450(CYP) 2C9 polymorphisms in patients receiving warfarin. J. Am. Coll. Surg. 194 (2002) 267-273
22. Margaglione M., Brancaccio V., Ciampa A., and Di Minno G. Reply to rebuttal: gene variants of the cytochrome P450 CYP2C9 affect oral anticoagulation with warfarin. Thromb. Haemost. 86 (2001) 938
23. Ogg M.S., Brennan P., Meade T., and Humphries S.E. CYP2C9*3 allelic variant and bleeding complications. Lancet 354 (1999) 1124
24. Steward D.J., Haining R.L., Henne K.R., et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 7 (1997) 361-367
25. Takahashi H., and Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet. 40 (2001) 587-603
26. Takahashi H., Ieiri I., Wilkinson G.R., et al. 5′-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood 103 (2004) 3055-3057